(AOF) – Eli Lilly is expected to fall in pre-market trading on Wall Street after the announcements made by its main competitor in the weight-loss drug market, Novo Nordisk, during its investor day. According to Reuters, the Danish laboratory has delivered the first clinical data for its highly anticipated anti-obesity drug, amycretin: it would have brought about greater weight loss compared to that brought about by its flagship product, Wegovy.